Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 39 for “"Programmed Cell Death Ligand 1"”.
-
Programmed cell death-ligand 1 (PD-L1) expression in HIV-associated diffuse large B-cell lymphoma – role and regulation
Diffuse Large B cell Lymphoma (DLBCL) is an aggressive disease that displays striking heterogeneity at both the molecular and clinical levels; and as a result, up to 40% of patients relapse or are refractory to standard first-line therapy. DLBCL is the most common subtype of lymphoma affecting …
-
Η έκφραση του συνδέτη του μορίου προγραμματισμένου κυτταρικού θανάτου PD-L1 (programmed cell death ligand-1) στον κολο-ορθικό καρκίνο
… του προγραμματισμένου κυτταρικού θανάτου PD-1 (programmed cell death), ο συνδέτης του PD-L1 (PD ligand), η πρωτεΐνη 4 σχετιζόμενη με τα κυτταροτοξικά Τ-λεμφοκύτταρα CTLA4 (cytotoxic T-lymphocyte associated protein 4), το γονίδιο ενεργοποίησης των λεμφοκυττάρων LAG-3 (lymphocyte activation gene) …
-
Modulations of Programmed Cell Death-Ligand 1 and Multidrug-Resistance Protein 5 in Triple-Negative Breast Cancer by Kānuka Leaf Extract
… because they can simultaneously target cancer cell vulnerabilities and modulate the tumour immune microenvironment. Within this context, the present thesis provides the first comprehensive evaluation of Kunzea ericoides (kānuka) leaf extract as a potential anticancer and chemo sensitising agent …
-
Optimierte In-vitro-Testung von Fremdstoffen auf hautsensibilisierendes Potenzial durch CRISPR/Cas9-vermittelten Knockout des Arylhydrocarbon-Rezeptors und Antikörperblockade des inhibitorischen Moleküls programmed cell death-ligand 1
Aus tierschutzrechtlichen und ethischen Gründen werden seit einigen Jahren vermehrt Alternativen zu den regulatorisch verbindlichen Tierversuchen entwickelt. Einer der standardmäßig zu testenden Endpunkte in der Chemikalienzulassung ist die Sensibilisierung durch Hautkontakt. Für diesen Endpunkt …
-
Exploring the Regulation of PD-L1 Expression as a Function of Stiffness via Mechanotransduction
… is often characterized by an upregulation of programmed cell death ligand 1 (PD-L1) on its surface which aids cancer immune invasion and tumor progression. As the tumor progresses, it often has tissue stiffening which is linked with metastasis and poor patient outcome. Recent studies have …
-
Characterizing PD-L1-Targeting Extracellular Vesicles Produced by Oncolytic Vaccinia Virus Infection
Tumour cells evade immune responses by multiple mechanisms in the tumour microenvironment, including through the expression of immunosuppressive molecules. The programmed cell death ligand 1 (PD-L1) plays a major role in this immunosuppression, and its expression is often up regulated as a result …
-
Η σημασία της έκφρασης του προσδέτη της πρωτεΐνης 1 προγραμματισμένου κυτταρικού θανάτου (PD-L1) και των κυτταροτοξικών CD8 λεμφοκυττάρων σε χαμηλής διαφοροποίησης αδενοκαρκινώματα του ενδομητρίου
Background: To evaluate the expression of programmed cell death-ligand 1 (PD-L1) and CD8 in high-grade endometrial carcinomas and relate it to several clinicopathological parameters. Methods: One hundred and one (101) patients with high-grade endometrial carcinomas who were completely surgically …
-
The impact of the liver microenvironment on the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic cancer
… the 4th most common cause of cancer-related deaths. Lacking specific symptoms, PDAC is mostly diagnosed at a locally advanced or metastatic stage, with the liver representing the main site of metastases and hepatic myofibroblasts (HMF) playing a pivotal role in metastatic outgrowth. To date, …
-
The Biological and Immunological Effects of Irreversible Electroporation and Combination Therapy Options for the Improving the Treatment of Pancreatic Cancer
… electrical pulses to form microlesions in cell membranes and induce cell death. While IRE has had significant impact in pancreatic cancer treatment in clinical trials, little is known on the biological and immunological effects of IRE on pancreatic cancer. By studying the effects of IRE on …
-
Rationally designing strategies to augment checkpoint therapy in cancer
… focuses on designing a novel treatment for hepatocellular carcinoma (HCC), which is a type of primary liver cancer and is in the top 3 causes of cancer related deaths owing to most patients being diagnosed at advanced stage of the disease. This first research chapter uses reovirus, an oncolytic …
-
Multi-omics analysis and modelling of T cell immunity and interferon signalling pathways for engineered T cell therapy
This thesis examines the nature of T cells through the lens of genomics. It delves into type I interferon (IFN)-mediated signalling in the tumour microenvironment (TME), focusing on the GMP-AMP synthase (cGAS)-stimulator of IFN genes (STING) pathway, and explores novel strategies to optimise T …
-
ELUCIDATING THE ROLE OF THE TYROSINE PHOSPHATASE, SHP-2, IN REGULATION OF PD-L1 EXPRESSION IN NON-SMALL LUNG CANCER USING BOTH BIOCHEMICAL ANALYSES AND REAL-WORLD GENOMIC INFORMATION
… inhibitors (ICIs), especially those that target programmed cell death protein 1 (PD-1) and programmed cell death ligand-1 (PD-L1), have been shown to provide substantial clinical benefit in many patients with non-small cell lung cancer (NSCLC). While these therapeutic agents can be highly …
-
Immunotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: biological landscape and prognostic biomarkers to improve patients' stratification
Head and neck squamous cell carcinoma (HNSCC) is the eight most frequent cancer in the world, and approximately 2/3 of the patients are diagnosed at locally advanced stages (stage III or IV). Despite improvements in HNSCC management and the aggressiveness of first-line curative treatment, 65% of …
-
Harnessing DNA nanoarchitecture to overcome immunoevasion in cancer
… a patient’s own immune system to fight malignant cells. However, the clinical application of immunotherapy has been hindered by the immunosuppressive tumor microenvironment generated by cancer cells as a mechanism to impede immune function and evade immune detection. Clinically used …
-
Resposta imune e mecanismos de evasão na carcinogênese de lábio: um estudo imunoistoquímico
… recognize and destroy malignant or altered cells. However, through immunosuppressive strategies, such as the signaling pathways of the programmed cell death ligand-1 (PD-L1) and human leukocyte antigen-G (HLA-G), these mutated cells often escape the antitumor immune response. The aim of this …
-
Έλεγχος της έκφρασης του υποδοχέα PD-L1 σε θηλώδη καρκινώματα θυρεοειδούς αδένα, διερεύνηση της μεταξύ τους σχέσης και της χρήσης του ως διαγνωστικό και προγνωστικό δείκτη
Background: Programmed cell death ligand 1 (PD-L1) expression is a well-established prerequisite for the use of immune checkpoint inhibitors and is increasingly recognized as a prognostic biomarker in various malignancies. However, its prognostic significance in thyroid cancer (TC), particularly …
-
Επίπεδα αγγειογενετικών αυξητικών παραγόντων στον ορό ασθενών με μη μικροκυτταρικό καρκίνο πνεύμονα πριν και μετά τη χορήγηση ανοσοθεραπείας, προγνωστική και προβλεπτική αξία
A complex interplay between immune cells and abnormal tumor vasculature in the tumor microenvironment has been previously shown in preclinical studies, while clinical data suggest that angiogenesis biomarkers may be useful as predictors of prognosis and treatment response in immunotherapy-treated …
Page 1 of 2